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Background/Aims: Renal hypoxia is involved in the pathogenesis of diabetic nephropathy. Pentoxifyllin (PTX), a non-
selective phosphodiesterase inhibitor, is used to attenuate peripheral vascular diseases. To determine whether PTX can 
improve renal hypoxia, we investigated its effect in the streptozocin (STZ)-induced diabetic kidney.
Methods: PTX (40 mg/kg, PO) was administered to STZ-induced diabetic rats for 8 weeks. To determine tissue 
hypoxia, we examined hypoxic inducible factor-1α (HIF-1α), heme oxygenase-1 (HO-1), vascular endothelial growth 
factor (VEGF), and glucose transporter-1 (GLUT-1) levels. We also tested the effect of PTX on HIF-1α in renal tubule 
cells. 
Results: PTX reduced the increased protein creatinine ratio in diabetic rats at 8 weeks. HIF-1α, VEGF, and GLUT-
1 mRNA expression increased significantly, and the expression of HO-1 also tended to increase in diabetic rats. PTX 
significantly decreased mRNA expression of HIF-1α and VEGF at 4 and 8 weeks, and decreased HO-1 and GLUT-
1 at 4 weeks. The expression of HIF-1α protein was significantly increased at 4 and 8 weeks in tubules in the diabetic 
rat kidney. PTX tended to decrease HIF-1α protein expression at 8 weeks. To examine whether PTX had a direct effect 
on renal tubules, normal rat kidney cells were stimulated with CoCl2 (100 μM), which enhanced HIF-1α mRNA and 
protein levels under low glucose conditions (5.5 mM). Their expressions were similar even after high glucose (30 mM) 
treatment. PTX had no effect on HIF-1α expression.
Conclusions: PTX attenuates tubular hypoxia in the diabetic kidney. 
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INTRODUCTION
Chronic hypoxia is involved in the pathogenesis of 
chronic renal injury, such as diabetic nephropathy. Hy-
poxic injury can induce tubulointerstitial fibrosis and 
atrophy [1,2]. These tubulointerstitial changes are as-
sociated with structural and functional deterioration of 
the renal vasculature [3-5]. 
Glomerular and tubular hypoxia may be induced by 
hyperglycemia or dysregulation of the glomerular arte-
rioles in diabetic nephropathy. Intra-renal oxygen ten-
sion decreases in the diabetic kidney, especially in the 164    The Korean Journal of Internal Medicine Vol. 27, No. 2, June 2012
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outer medullary region [6,7]. The changes in intrarenal 
microcirculation are unclear, but oxygen consumption 
is increased in the diabetic kidney, suggesting its vul-
nerability to hypoxia [8].
Hypoxia impairs various cellular functions. Hypoxic 
cells synthesize hypoxia-inducible transcription fac-
tors (HIF) and heme oxygenase (HO) to minimize tis-
sue damage. HIF, which is one of the most important 
hypoxia-related molecules, plays a role in adaptation to 
a low oxygen supply [9,10]. HIF is produced in response 
to hypoxia in various renal cell types [11].
Cyclic-3', 5'-phosphdiesterase (PDE) degrades cy-
clic-3', 5'-adenosine monophosphate and cyclic 3', 
5'-guanosine monophosphate affecting their intra- and 
extra-cellular concentrations [12]. PDE 3 inhibitor im-
proves endothelial function and inflammatory changes 
in damaged vascular smooth cells stimulated by tumor 
necrosis factor-α [13,14]. The PDE 4 inhibitor rolipram 
also reduces expression of adhesion molecules, such as 
P-selectin and E-selectin, which are critical substances 
in the binding of white blood cells to endothelial cells 
[15]. In the clinical field, PDE inhibitors are used to treat 
peripheral vascular and bronchoconstrictive diseases 
[16,17]. 
Despite the fact that hypoxia is involved in the patho-
genesis of diabetic nephropathy, restoration of renal tu-
bular hypoxia is difficult. Based on the hypothesis that 
PDE inhibitors may improve renal tubular hypoxia, we 
investigated whether pentoxifyllin (PTX), a nonselec-
tive PDE inhibitor, may attenuate the hypoxic condition 
in streptozocin (STZ)-induced type 1 diabetic rats.
METHODS
Animal study and experimental design
Male Sprague-Dawley rats weighing 200-220 g were 
divided into three groups. Twelve rats in which diabetes 
mellitus was not induced were used as controls. Diabe-
tes mellitus was induced by intraperitoneal injection 
of STZ, 65 mg/kg body weight (Sigma-Aldrich, Saint 
Louis, MO, USA). Diabetic rats (n = 26) were further 
randomized into a diabetic control group and a treat-
ment group. Diabetes in the rats was confirmed by a 
> 300 mg/dL tail blood sugar concentration 48 hours 
after STZ injection. Rats in the PTX group were treated 
with 40 mg/kg PTX (Sigma-Aldrich). Fourteen of the 
rats were sacrificed and the remainder were kept for an 
additional 4 weeks. Six-hour urine was collected using 
metabolic cages. Then the rats were anesthetized by in-
traperitoneal injection of sodium pentobarbital (50 mg/
kg). The cortex of one kidney in Trizol reagent (Invitro-
gen, Carlsbad, CA, USA) was stored at -70°C. The other 
kidney was perfused with normal saline and fixed in 4% 
paraformaldehyde. 
Body and kidney weights were measured upon sacri-
fice. Blood glucose levels were determined using stan-
dard techniques. Urinary protein was measured with 
a Pierce BCA Protein Assay Kit (Pierce Biotech Inc., 
Rockford, IL, USA), and then normalized to urine cre-
atinine measured by the Alkaline Picrate method. 
Cell culture and experimental design 
Immortalized normal rat kidney (NRK) cells were 
acquired from the American Tissue Culture Collec-
tion (Rockville, MD, USA). These cells were cultured in 
DMEM (GibCo BRL, Carlsbad, CA, USA), supplemented 
with 10% heat-inactivated fetal bovine serum (FBS), 
100 U/mL penicillin, and 100 mg/mL streptomycin at 
37°C in a humidified atmosphere of 95% air and 5% 
CO2. Then subconfluent cells were cultured in 0.1% FBS 
for 24 hours before use in experiments. The cells were 
incubated in 5.5 mM (normal glucose, NG) or 30 mM 
(high glucose, HG) D-glucose. To induce hypoxia, 100 
μM CoCl2 was administered 6 hours prior. Cells were 
pretreated with PTX 30 minutes before drug treatment. 
All experimental groups were cultured in triplicate and 
harvested at 6 and 24 hours for extraction of total RNA 
and protein. 
Real-time reverse transcriptase-polymerase chain 
reaction (RT-PCR)
Total RNA was extracted from renal cortical tissues 
or cells with Trizol reagent. Total RNA was reverse 
transcribed into cDNA using cDNA synthesis (Fer-
mentas, Burlington, Canada) and RNA PCR (Applied 
Biosystems, Carlsbad, CA, USA) kits in a 20 μL mixture 
containing 0.5 μg RNA, 50 mM KCl, 50 mM Tris/HCl, 4 
mM MgCl2, 1 mM of each dNTP, oligo-(dT) primers, 20 
units of RNAse inhibitor, and 50 units of MuLV reverse 
transcriptase. The reaction mixture was incubated for 
10 minutes at 37°C, 60 minutes at 42°C, and then heat-Sun HK, et al. PDE inhibitor on hypoxia in diabetic kidney   165
http://dx.doi.org/10.3904/kjim.2012.27.2.163 http://www.kjim.or.kr
ed at 90°C for 5 minutes in a thermocycler (GeneAmp 
PCR system 2700, Applied Biosystems). RT-PCR was 
performed using standard three-step cycling conditions 
with SYBR Green Mastermix. Primers were designed 
from the respective gene sequences using the Primer 
3 software. The nucleotide sequences of each primer 
were as follows: HIF-1α (sense 5' ACAGCACATTCA-
CAGCTCCCCA, anti-sense 5' TGTGGCTACCATGTACT-
GCTGGC3'), HO-1 (sense GTGCCCTTGGTAGTCGGC-
GT, anti-sense CCTCAAAAGACAGCCCTACTTGGTT), 
vascular endothelial growth factor (VEGF; sense 
AGCCTTGTTCAGAGCGGAGAA, anti-sense TAACT-
CAAGCTGCCTCGCCTT), glucose transporter-1 (GLUT-
1; sense CAAACTGACAGATCTCGGGC, anti-sense 
TTCTGGAGCCATCAAAGTCC), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; sense TGCACCAC-
CAACTGCTTAGC, anti-sense 5'-GGCATGGACTGTG-
GTCATGAG-3'). The expression levels of all genes were 
normalized to that of the housekeeping gene GAPDH.
Immunohistochemical staining for HIF-1α and 
HO-1
For immunohistochemical staining, renal tissue was 
immediately fixed in 10% neutral buffered formalin, 
cast in paraffin, and then sliced into 4 μm thick sec-
tions. After removal of paraffin in xylene and dehydra-
tion in a graded alcohol series, slides were immersed in 
distilled water. Kidney sections were transferred to a 10 
mM citrate buffer solution for antigen retrieval at a pH 
of 6.0 and then incubated at a sub-boiling temperature 
for 15 minutes. After washing with water, 3.0% H2O2 
was applied for 15 minutes to block endogenous peroxi-
dase. To inhibit nonspecific staining, slides were incu-
bated at room temperature for 1 hour with normal goat 
serum. The primary antibodies mouse monoclonal anti-
human HIF-1α (Chemicon, Billerica, MA, USA, 1:500) 
and rabbit polyclonal anti-rat HO (Abcam, Cambridge, 
MA, USA, 1:1,000) were added to the slides followed by 
overnight incubation at 4°C. Negative control sections 
were stained under identical conditions by substituting 
the primary antibody with equivalent concentrations of 
normal rabbit IgG. 
Expression was evaluated by semi-quantitatively 
grading staining within tubules. In this method, each 
score reflects changes in the extent rather than in the 
intensity of staining, and depends on the percentage 
of the grid field that stains positive. Four scores were 
awarded: 0, absent or < 25% positive staining; 1, 25-
50% positive staining; 2, 50-75%; and 3, > 75% positive 
staining. The average score of each sample was calcu-
lated. Each slide was scored by an observer blinded to 
the experimental details. 
Western blotting 
Cells were lysed in buffer (150 mM NaCl, 50 mM Tris-
HCl, pH 8.0, 1% Triton X-100, 1 mM phenylmethylsul-
fonylfluoride), and total protein concentrations were 
quantified using the advanced protein assay reagent 
(Bio-Rad, Hercules, CA, USA) in a spectrophotometer. 
An aliquot of 40 μg protein was electrophoresed on 6% 
or 10% SDS-polyacrylamide gels under denaturing con-
ditions. Then proteins were transferred to polyvinyli-
dene difluoride membranes (Immobilon-P, Millipore, 
Billerica, MA, USA) for 120 minutes at 250 mA. After 
blocking in blocking solution (PBS, 0.15% Tween-20, 
5% non-fat milk) for 1 hour at room temperature, mem-
branes were hybridized overnight at 4°C using mouse 
monoclonal anti-human HIF-1α (Chemicon, 1:500), rab-
Table 1. Biochemical parameters in experimental animals
Experimental group Ratio
a
Blood glucose, mg/dL Proteinuria, mg/mgCr
4 wk Control rats 3.07 ± 0.22   100.6 ± 5.86 6.95 ± 0.38
DM rats 8.28 ± 1.10
b
 397.9 ± 52.7
b
  12.2 ± 1.46
b
DM with PTX  7.12 ± 0.77 443.0 ± 49.8   13.3 ± 1.45
8 wk Control rats 3.21 ± 0.41 106.8 ± 5.35   7.22 ± 1.24
DM rats   7.46 ± 0.67  478.1 ± 31.2
b
  13.9 ± 4.61
b
DM with PTX 8.35 ± 1.05 480.2 ± 27.1 9.88 ± 1.67
c
Values are presented as mean ± SD.
DM, diabetes mellitus; PTX, pentoxifyllin.
aKidney (mg)/body weight (g). 
bp < 0.05, vs. control. 
cp < 0.05, vs. DM.   166    The Korean Journal of Internal Medicine Vol. 27, No. 2, June 2012
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bit polyclonal ant-rat HO-1 (Abcam, 1:1,000), and anti-
rat β-actin (Abcam, 1:3,000). Then the membranes were 
washed four times with PBS-Tween-20, and incubated 
for 30 minutes at room temperature with horseradish 
peroxidase-conjugated secondary antibody, diluted 
to 1:3,000. Specific signals were detected using the 
enhanced chemiluminenscence method (Amersham, 
Buckinghamshire, UK). Equal protein loading was con-
firmed by β-actin. 
Statistical analysis
We used a nonparametric analysis because most vari-
ables were not normally distributed, even after loga-
rithmic transformation. The t test was used to compare 
groups, and a value of p < 0.05 was defined as statisti-
cally significant. All statistical analyses were performed 
using SPSS version 10.0 (SPSS Inc., Chicago, IL, USA). 
Data are expressed as mean ± standard derviation. 
Figure 1. mRNA expression of HIF-1α (A), HO-1 (B), GLUT-1 (C), and VEGF (D). Values are presented mean ± SD. HIF-1α, hypoxic 
inducible factor-1α; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HO-1, heme oxygenase-1; GLUT-1, glucose transporter-1; 
VEGF, vascular endothelial growth factor. 
ap < 0.05, diabetic rats (gray bar) vs. control rats (white bar); 
bp < 0.05, diabetic rats with 




DSun HK, et al. PDE inhibitor on hypoxia in diabetic kidney   167
http://dx.doi.org/10.3904/kjim.2012.27.2.163 http://www.kjim.or.kr
RESULTS
Baseline characteristics of diabetic rats
Blood glucose concentration and kidney weight were 
significantly higher in STZ-induced diabetic rats than in 
control rats at 4 and 8 weeks. The increased blood glu-
cose concentration and kidney weight were unaffected 
by PTX treatment. 
The protein creatinine ratio was significantly higher 
in diabetic rats than in control rats at 4 and 8 weeks.
This increased ratio decreased in diabetic rats after 
PTX treatment at 8 weeks (13.9 ± 4.61 vs. 9.88 ± 1.67 
mg/mgCr; p < 0.05) (Table 1).
Hypoxia-related factor mRNA levels
HIF-1α, VEGF, and GLUT-1 mRNA levels were sig-
nificantly higher in diabetic rats; that of HO-1 tended 
to increase in diabetic rats. PTX significantly decreased 
both HIF-1α and VEGF mRNA expression at 4 and 8 
weeks, and decreased that of HO-1 and GLUT-1 at 4 
weeks (Fig. 1).
Figure 2. Hypoxic inducible factor-1α (HIF-1α) immunohistochemistry in experimental animals. Representative HIF-1α 
immunostaining findings (A) and scores (B) in control (Cont), diabetic rats (DM), and DM with pentoxifyllin (PTX). HIF-1α are strongly 
stained in the distal tubule of the DM and PTX groups, whereas no staining in the control group. Values are presented mean ± SD. 
ap < 
0.05, diabetic rats (gray bar) vs. control rats (white bar).
Figure 3. Heme oxygenase-1 (HO-1) immunohistochemistry in experimental animals. Representative HO-1 immunostaining findings 
(A) and scores (B) in control (Cont), diabetic rats (DM), and DM with pentoxifyllin (PTX). HO-1 is stained strongly in the proximal 
tubular cytoplasm in both the DM and PTX groups.
a
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Immunohistochemical staining for HIF-1α and HO
HIF-1α synthesis in the diabetic rat kidney increased 
at both 4 and 8 weeks. At 8 weeks, its expression was 
consistently higher than that in control rats. HO-1 ex-
pression was not different compared to control rats. 
These molecules were expressed mainly in the tubules, 
not in the glomeruli. PTX tended to decrease HIF-1α 
protein expression by 36% at 8 weeks (Figs. 2 and 3).
Effect of PTX on CoCl2-stimulated NRK cells
To investigate whether PTX directly affected renal 
tubules, NRK cells were stimulated with CoCl2 (100 
μM), which induced HIF-1α mRNA production under 
NG conditions. HIF-1α mRNA was also increased under 
HG conditions. Production was similar even after HG 
treatment. HG and CoCl2 showed no synergistic effect 
on HIF-1α. HIF-1α protein showed a similar pattern. 
HO-1 mRNA production tended to increase in response 
to CoCl2, and protein expression was similar to mRNA 
expression (Fig. 4).
DISCUSSION
PTX reduced HIF-1α and VEGF expression, which are 
upregulated in diabetic rats, but had no direct effect on 
HIF-1α in NRK cells stimulated with CoCl2 under both 
NG and HG conditions. These results suggest that PTX 
attenuates renal hypoxia in the diabetic kidney.
The effect of hyperglycemia on HIF expression is un-
clear, and depends on cell type. Hyperglycemia inhibits 
HIF expression, affecting cell survival [18,19]. VEGF is 
also suppressed by hypoxic stimuli in diabetic rats [20]. 
However, hyperglycemia itself stimulates hypoxia-relat-
ed molecules [8]. In the present study, CoCl2 upregulat-
ed HIF-1α expression in renal tubule cells, but did not 
further affect HIF-1α expression after HG stimulation.
Hypoxia plays an important role in the pathogenesis 
of diabetic nephropathy due to the relative hypoxia 
induced by peritubular flow disturbance in hyperfiltra-
tion induced by hyperglycemia [21-23]. In addition, 
peritubular capillary damage reduces renal blood flow, 
subsequently increasing the intrarenal oxygen require-
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Figure 4. Effect of pentoxifyllin (PTX) on hypoxic inducible 
factor-1α (HIF-1α) mRNA (A), and heme oxygenase-1 (HO-1) 
mRNA (B) and protein (C) expression in cultured normal rat 
kidney cells (NRK) cells. CoCl2 stimulated HIF-1α in normal 
glucose (NG). There was no synergistic effect of HG and CoCl2 on 
HIF-1α. HIF-1α exhibited a similar pattern. Values are presented 
mean ± SD. 
ap < 0.05, vs. NG.
a
C
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nal hypoxia using erythropoietin, prolyl hydroxylase 
inhibitor, and VEGF [25-28]; however, the efficacies of 
these compounds are not clear. A recent trial directly 
increased intrarenal HIF and HO expression to reduce 
renal tubular damage [29].
The renoprotective effect of PTX in diabetic nephrop-
athy is unclear. Although a metaanalysis showed that 
PDE inhibitor reduces proteinuria in patients with dia-
betic nephropathy, PTX has not been used in patients 
with diabetic nephropathy [30]. In animal studies, PDE 
inhibitors stimulated lipolysis and free fatty acid syn-
thesis, and improved insulin resistance and endothelial 
dysfunction [14,31,32]. It also affects peripheral and re-
nal blood flow [33,34], suggesting the possibility of at-
tenuating renal tubular blood flow. In the present study, 
PTX did not influence HIF-1α expression in NRK cells 
stimulated with CoCl2 and HG. The mechanism under-
lying the beneficial effect of PTX in the STZ-induced 
diabetic kidney seems to be related to improving renal 
blood flow by attenuating peritubular endothelial dys-
function, rather than having a direct effect. The mecha-
nism underlying the beneficial effect of PTX on renal 
hypoxia could be confirmed by measuring renal tubular 
blood flow. 
In conclusion, PTX, a peripheral vasodilator, reduced 
renal hypoxia in diabetic rats. In the future, direct mea-
surements of blood flow will further clarify the effect of 
PTX.  
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